Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of Lu AG09222 for prevention of migraine in adults with episodic and chronic migraine
2023-508821-28-00Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Jul 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of lu ag09222 in migraine and chronic migraine (3 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline in Monthly Migraine Diary (Weeks 1–12). Started Jul 2024; status: completed.
02
Drugs
lu ag09222
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on 2023-508821-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508821-28-00.